Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 8/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1280136 | 0.99 | CNR1 (0.39) | CNR1TRPV4LMNAGAAALK | |
| Bromide SCHEMBL1279726 | 0.99 | TRPV4 (0.40) | CNR1TRPV4LMNAGAAALK | |
| Sulfuric Acid SCHEMBL1279086 | 0.97 | CNR1 (0.40) | CNR1TRPV4LMNAGAAALK | |
| SCHEMBL1279061 | 0.96 | CNR1 (0.39) | CNR1TRPV4LMNAGAAALK | |
| SCHEMBL1279059 | 0.88 | L3MBTL1 (0.44) | CNR1TRPV4LMNAGAATRPM8 | |
| SCHEMBL693417 | 0.88 | TRPV4 (0.40) | CNR1TRPV4LMNAGAATSHR | |
| Hydrochloric Acid SCHEMBL1279717 | 0.87 | L3MBTL1 (0.43) | CNR1TRPV4LMNAGAATRPM8 | |
| Bromide SCHEMBL1279761 | 0.87 | L3MBTL1 (0.43) | CNR1TRPV4LMNAGAAKCNH2 | |
| SCHEMBL13157389 | 0.86 | CNR1 (0.35) | CNR1TRPV4KCNH2CYP3A4TRPM8 | |
| SCHEMBL12693504 | 0.86 | CNR1 (0.46) | CNR1TRPV4LMNATRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2627635-A1 | SALTS OF ARYLSULFONAMIDE CCR3 ANTAGONISTS | Axikin Pharmaceuticals, Inc. (US) | 2013-08-21 | — | — | EP | claimed |
| WO-2012051090-A1 | SALTS OF ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2012-04-19 | — | — | WO | claimed |
| US-20120088769-A1 | SALTS OF ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2012-04-12 | — | — | US | claimed |
| EP-2627635-A1 | SALTS OF ARYLSULFONAMIDE CCR3 ANTAGONISTS | Axikin Pharmaceuticals, Inc. (US) | 2013-08-21 | — | — | EP | disclosed |
| WO-2012051090-A1 | SALTS OF ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2012-04-19 | — | — | WO | disclosed |
| US-20120088769-A1 | SALTS OF ARYLSULFONAMIDE CCR3 ANTAGONISTS | AXIKIN PHARMACEUTICALS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088769-A1 | SALTS OF ARYLSULFONAMIDE CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | CNR1 52/4885TRPV4 762/4885LMNA 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.